Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) announced a collaboration with MSCI Inc. to create new thematic indexes focused on innovation in the life sciences, specifically targeting virology and oncology. This partnership will leverage Royalty Pharma's expertise in medical conditions and clinical trials to assist MSCI in developing index methodologies. The new indexes aim to capture performance metrics of companies delivering advanced therapeutic treatments. The launch is expected later this year, showcasing Royalty Pharma's commitment to monetizing its intellectual capital in life sciences.

Positive

• Collaboration with MSCI to expand index offerings in life sciences.
• Leveraging extensive expertise in clinical trials for index development.
• Focus on innovative therapeutic treatments in high-demand areas like virology and oncology.
• Potential for new indexed financial products like ETFs targeting the life sciences sector.

Negative

• None.

NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, to expand MSCI’s thematic index suite with the launch of new indexes that aim to capture long-term, cutting edge themes that will disrupt the life sciences, biotechnology and pharmaceutical industry groups.

Royalty Pharma will provide expertise on various medical conditions, clinical trials, transformative therapies, and technologies that may lead to breakthrough medical treatments that will assist MSCI to design a classification framework and index methodologies. The initial indexes will measure the performance of companies focused on delivering new and innovative therapeutic treatments related to virology and oncology.

Pablo Legorreta, founder and Chief Executive Officer at Royalty Pharma, stated: “As a leading funder of innovation in life sciences, we are extremely excited to collaborate with MSCI to develop innovative index solutions that will be licensed as the basis for indexed financial products such as ETFs targeting this dynamic sector. This collaboration leverages Royalty Pharma’s deep clinical and scientific knowledge built over decades, as well as the unique capabilities of our Strategy and Analytics team. This venture represents another example of Royalty Pharma’s creative approach to monetizing its existing intellectual capital through the creation of indexes that support investment in life sciences.”

Henry Fernandez, Chairman and Chief Executive Officer at MSCI, said: “The Covid-19 pandemic has had a profound impact on all aspects of society and has proven to be an accelerant for long-term, structural changes, particularly in the life sciences. As we have seen during this time, life sciences companies are pivotal to shaping and advancing the healthcare industry and have been critical to the development of approaches for prevention and treatment of diseases. MSCI is thrilled to partner with Royalty Pharma to design thematic indexes that capture companies at the forefront of this evolving landscape and having a positive impact on the future of our world.”

The MSCI indexes are planned to launch later this year.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com.

Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please reference our reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

What is the collaboration between Royalty Pharma and MSCI?

Royalty Pharma is collaborating with MSCI to create new thematic indexes aimed at capturing innovation in life sciences, particularly in virology and oncology.

When are the new MSCI indexes expected to launch?

The new MSCI indexes are planned to launch later this year.

What will the new indexes focus on?

The new indexes will focus on measuring the performance of companies delivering innovative therapeutic treatments in virology and oncology.

How will Royalty Pharma contribute to the index development?

Royalty Pharma will provide expertise on medical conditions, clinical trials, and transformative therapies to assist MSCI in designing index methodologies.